Cargando…
Gut microbiota mediated molecular events and therapy in liver diseases
Gut microbiota is a community of microorganisms that reside in the gastrointestinal tract. An increasing number of studies has demonstrated that the gut-liver axis plays a critical role in liver homeostasis. Dysbiosis of gut microbiota can cause liver diseases, including nonalcoholic fatty liver dis...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789060/ https://www.ncbi.nlm.nih.gov/pubmed/33505139 http://dx.doi.org/10.3748/wjg.v26.i48.7603 |
_version_ | 1783633157495455744 |
---|---|
author | Qi, Xiaoqiang Yang, Ming Stenberg, Joseph Dey, Rahul Fogwe, Leslie Alam, Muhammad Shawkat Kimchi, Eric T Staveley-O'Carroll, Kevin F Li, Guangfu |
author_facet | Qi, Xiaoqiang Yang, Ming Stenberg, Joseph Dey, Rahul Fogwe, Leslie Alam, Muhammad Shawkat Kimchi, Eric T Staveley-O'Carroll, Kevin F Li, Guangfu |
author_sort | Qi, Xiaoqiang |
collection | PubMed |
description | Gut microbiota is a community of microorganisms that reside in the gastrointestinal tract. An increasing number of studies has demonstrated that the gut-liver axis plays a critical role in liver homeostasis. Dysbiosis of gut microbiota can cause liver diseases, including nonalcoholic fatty liver disease and alcoholic liver disease. Preclinical and clinical investigations have substantiated that the metabolites and other molecules derived from gut microbiota and diet interaction function as mediators to cause liver fibrosis, cirrhosis, and final cancer. This effect has been demonstrated to be associated with dysregulation of intrahepatic immunity and liver metabolism. Targeting these findings have led to the development of novel preventive and therapeutic strategies. Here, we review the cellular and molecular mechanisms underlying gut microbiota-mediated impact on liver disease. We also summarize the advancement of gut microbiota-based therapeutic strategies in the control of liver diseases. |
format | Online Article Text |
id | pubmed-7789060 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-77890602021-01-26 Gut microbiota mediated molecular events and therapy in liver diseases Qi, Xiaoqiang Yang, Ming Stenberg, Joseph Dey, Rahul Fogwe, Leslie Alam, Muhammad Shawkat Kimchi, Eric T Staveley-O'Carroll, Kevin F Li, Guangfu World J Gastroenterol Minireviews Gut microbiota is a community of microorganisms that reside in the gastrointestinal tract. An increasing number of studies has demonstrated that the gut-liver axis plays a critical role in liver homeostasis. Dysbiosis of gut microbiota can cause liver diseases, including nonalcoholic fatty liver disease and alcoholic liver disease. Preclinical and clinical investigations have substantiated that the metabolites and other molecules derived from gut microbiota and diet interaction function as mediators to cause liver fibrosis, cirrhosis, and final cancer. This effect has been demonstrated to be associated with dysregulation of intrahepatic immunity and liver metabolism. Targeting these findings have led to the development of novel preventive and therapeutic strategies. Here, we review the cellular and molecular mechanisms underlying gut microbiota-mediated impact on liver disease. We also summarize the advancement of gut microbiota-based therapeutic strategies in the control of liver diseases. Baishideng Publishing Group Inc 2020-12-28 2020-12-28 /pmc/articles/PMC7789060/ /pubmed/33505139 http://dx.doi.org/10.3748/wjg.v26.i48.7603 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Minireviews Qi, Xiaoqiang Yang, Ming Stenberg, Joseph Dey, Rahul Fogwe, Leslie Alam, Muhammad Shawkat Kimchi, Eric T Staveley-O'Carroll, Kevin F Li, Guangfu Gut microbiota mediated molecular events and therapy in liver diseases |
title | Gut microbiota mediated molecular events and therapy in liver diseases |
title_full | Gut microbiota mediated molecular events and therapy in liver diseases |
title_fullStr | Gut microbiota mediated molecular events and therapy in liver diseases |
title_full_unstemmed | Gut microbiota mediated molecular events and therapy in liver diseases |
title_short | Gut microbiota mediated molecular events and therapy in liver diseases |
title_sort | gut microbiota mediated molecular events and therapy in liver diseases |
topic | Minireviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789060/ https://www.ncbi.nlm.nih.gov/pubmed/33505139 http://dx.doi.org/10.3748/wjg.v26.i48.7603 |
work_keys_str_mv | AT qixiaoqiang gutmicrobiotamediatedmoleculareventsandtherapyinliverdiseases AT yangming gutmicrobiotamediatedmoleculareventsandtherapyinliverdiseases AT stenbergjoseph gutmicrobiotamediatedmoleculareventsandtherapyinliverdiseases AT deyrahul gutmicrobiotamediatedmoleculareventsandtherapyinliverdiseases AT fogweleslie gutmicrobiotamediatedmoleculareventsandtherapyinliverdiseases AT alammuhammadshawkat gutmicrobiotamediatedmoleculareventsandtherapyinliverdiseases AT kimchierict gutmicrobiotamediatedmoleculareventsandtherapyinliverdiseases AT staveleyocarrollkevinf gutmicrobiotamediatedmoleculareventsandtherapyinliverdiseases AT liguangfu gutmicrobiotamediatedmoleculareventsandtherapyinliverdiseases |